MedPath

Trandolapril

Generic Name
Trandolapril
Brand Names
Mavik, Tarka
Drug Type
Small Molecule
Chemical Formula
C24H34N2O5
CAS Number
87679-37-6
Unique Ingredient Identifier
1T0N3G9CRC
Background

Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Indication

用于高血压、心力衰竭以及延迟和逆转高血压所引起的心脏病理变化。

Associated Conditions
Heart Failure, Hypertension, Left Ventricular Dysfunction
Associated Therapies
-

Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-07-19
Last Posted Date
2010-07-19
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
52
Registration Number
NCT01164800
Locations
🇮🇳

Wellquest Clinical Research, Mumbai, Maharashtra, India

Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2010-07-19
Last Posted Date
2010-07-19
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
52
Registration Number
NCT01164787
Locations
🇮🇳

Wellquest Clinical Research, Mumbai, Maharashtra, India

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2009-04-24
Last Posted Date
2014-06-17
Lead Sponsor
University of Florida
Target Recruit Count
24
Registration Number
NCT00887510
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Phase 4
Completed
Conditions
Heart Failure
Ventricular Dysfunction, Left
Interventions
Drug: Captopril
Drug: Enalapril
Drug: Lisinopril
Drug: Ramipril
Drug: Trandolapril
Drug: Bisoprolol
Drug: Carvedilol
Drug: Metoprolol succinate
Drug: Candesartan
Drug: Valsartan
Drug: Eplerenone
Drug: Spironolactone
Drug: Diuretics
Drug: HF treatment according to Swedish guidelines
Procedure: Blood samples
Procedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
First Posted Date
2006-10-25
Last Posted Date
2012-06-25
Lead Sponsor
AstraZeneca
Target Recruit Count
252
Registration Number
NCT00391846
Locations
🇸🇪

Research Site, Vaxjo, Sweden

A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)

Phase 4
Completed
Conditions
Hypertension
Diabetes
Interventions
Drug: trandolapril/verapamil
Drug: placebo
Drug: trandolapril
Drug: verapamil
First Posted Date
2005-10-10
Last Posted Date
2008-07-15
Lead Sponsor
Abbott
Target Recruit Count
1204
Registration Number
NCT00235014

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2005-10-06
Last Posted Date
2008-07-22
Lead Sponsor
Abbott
Target Recruit Count
2000
Registration Number
NCT00233532
© Copyright 2025. All Rights Reserved by MedPath